Abstract
The osteopetrotic (op/op) rat mutation is a lethal mutation in which decreased osteoclast function (bone resorption) coexists with markedly elevated serum levels of 1,25-dihydroxyvitamin D3[1,25(OH)2D3]. Increased circulating levels of 1,25(OH)2D3 have been reported in other osteopetrotic animal mutations and in some osteopetrotic children. This study examined the effects of 1,25(OH)2D3 infusions on serum and skeletal parameters in normal and mutant rats of op stock. We also examined vitamin D receptor expression and binding in bone cells from op normal and mutant animals. Four-week-old normal and mutant rats were infused either with propylene glycol (used as controls) or with 12.5–125 ng of 1,25(OH)2D3/d using osmotic minipumps implanted subcutaneously for 1 wk. Sera were analyzed for calcium, phosphorus, and 1,25(OH)2D3 levels. Histomorphometric analyses of proximal tibiae from treated normal (50 ng/d) and op mutant (125 ng/d) rats and their vehicle-infused controls were performed. Normal animals infused with 1,25(OH)2D3 exhibited a dose-dependent increase in serum calcium levels. Histomorphometric analyses of metaphyseal bone within the primary spongiosae region showed that 1,25(OH)2D3 increased osteoclast number with a reduction in osteoblast surface associated with a decrease in growth plate cartilage thickness. However, similar analyses on secondary spongiosae showed a decrease in osteoclast number and surface associated with an anabolic response. Op mutants infused with 1,25(OH)2D3 did not exhibit any change in serum calcium levels or histomorphometric parameters related to growth plate cartilage and metaphyseal bone compared with mutant controls. Vitamin D mRNA and protein levels were increased two- to threefold in op mutants compared to age-matched normal rats. However, binding affinity of 1,25(OH)2D3 to its receptor was similar between op mutant and normal animals. High dose calcitriol therapy, under the conditions and period of treatment used in this study, failed to stimulate bone turnover in op rats, suggesting that they are resistant to the skeletal effects of 1,25(OH)2D3. The failure of osteoclast activation in response to 1,25(OH)2D3 treatment may be associated with osteoblast incompetence in this mutation.
Similar content being viewed by others
References
Marks, S. C. Jr. (1989). Am. J. Med. Genetics 34, 43–54.
Seifert, M. F., Popoff, S. N., Jackson, M. E., MacKay, C. A., Cielinski, M., and Marks, S. C. Jr. (1993). Clin. Orthop. 294, 23–33.
Schneider, G. B., Key, L. L., and Popoff, S. N. (1998). The Endocrinologist 8, 409–417.
Popoff, S. N. and Marks, S. C. Jr. (1995). Bone 17, 437–445.
Popoff S. N. and Schneider, G. B. (1996). Mol. Med. Today 2, 349–358.
Walker, D. G. (1975). J. Exp. Med. 142, 651.
Ballet, J. J. and Griscelli, C. (1978). In: Mechanisms of localized bone loss. Horton, J. E., Tarpley, T. M. and Davis, W. F. (eds.). Information Retrieval: Washington, DC.
Coccia, P. F., Krivit, W., Cervenka, J., Clawson, C., Kersey, J. H., Kim, T. H., Nesbit, M. E., Ramsay, N. K. C., Warkentin, P. I., Teitelbaum, S. L., Kahn, A. J., and Brown, D. M. (1980). N. Engl. J. Med. 302, 701–708.
Seiff, C. A., Levinsky, R. J., Rogers, D. W., Muller, K., Chessels, J. M., Pritchard, J., Casey, A., and Hall, C. M. (1983). Lancet. 1, 437–441.
Sorell, M., Kapoor N., Kirkpatrick, D., Rosen, J. F., Chaganti, R. S. K., Lopez, C., Dupont, B., Pollack, M. S., Terrin, B. N., Harris, M. B., Vine, D., Rose, J. S., Goosen, C., Lane, J., Good, R. A., and O'Reilly, R. J. (1981). Am. J. Med. 70, 1280–1287.
Marks, S. C. Jr. (1977). Am. J. Anat. 149, 289–297.
Marks, S. C. Jr., Seifert, M. F. and McGuire, J. L. (1984). Metab. Bone Dis. Rel. Res. 5, 183–186.
Popoff, S. N. and Marks, S. C. Jr. (1991). Am. J. Anat. 192, 274–280.
Seifert, M. F. and Marks, S. C. Jr. (1987). Tiss. Cell 19, 29–37.
Gerritsen, E. J., Vossen, J. M., Fasth, A., Friedrich, W., Morgan, G., Padmos, A., Vellodi, A., Porras, O., O'Meara, A. and Porta, F. (1994). J. Pediatr. 125, 896–902.
Solh, H., DaCunha, A. M., Giri, N., Padmos, A., Spence, D., Clink, H., Ernst, P., and Sakati, N. (1995). J. Pediatr. Hematol. Oncol. 17, 350–355.
Hermey, D. C., Ireland, R. A., Zerwekh, J. E., and Popoff, S. N. (1995). Am. J. Physiol. 268 (Endocrinol. Metab.) 31, E312-E317.
Popoff, S. N., Osier, L. K., Zerwekh, J. E., and Marks, S. C. Jr. (1994). Bone 15, 515–522.
Popoff, S. N., Osier, L. K., Zerwekh, J. E., and Marks, S. C. Jr. (1992). In: The biological mechanisms of tooth movement and craniofacial adaption. Davidovitch, Z. (ed.), EBSCO Media: Birmingham, AL.
Seifert, M. F., Gray, R. W., and Bruns, M. E. (1990). Am. J. Physiol. 258 (Endocrinol. Metab.), 21, E377-E381.
Zerwekh, J. E., Marks, S. C. Jr., and McGuire, J. L. (1987). Bone Miner. 2, 193–199.
Cournot, G., Trubert-Thuil, C. L., Petrovic, M., Boyle, A., Cormier, C., Girault, D., Fischer, A., and Garabedian, M. (1992). J. Bone Miner. Res. 7, 1–10.
Glorieux, F., Pettifor, J., Marie, P., Delvin, E., Travers, R., and Shepard, N. (1981). Metab. Bone Dis. Relat. Res. 3, 143–150.
Key, L., Carnes, D., Cole, S., Holtrop, M., Bar-Shavit, Z., Shapiro, F., Arceci, R., Steinberg, J., Gundberg, C., Kahn, A., Teitelbaum, S., and Anast, C. (1984). N. Engl. J. Med. 310, 409–415.
Holtrop, M. E., Cox, K. A., Clark, M.B., Holick, M. F., and Anast, C. S. (1981). Endocrinology 108, 2293–2301.
Marie, P. J. and Travers, R.. (1983). Calcif. Tissue Int. 35, 418–425.
Popoff, S. N., McGuire, J. L., Zerwekh, J. E., and Marks, S. C. Jr. (1989). J. Bone Miner. Res. 4, 57–67;
Key, L. L. and Baron, R. (1986). J. Bone Miner. Res. 1, 111A.
Van Lie Peters, E. M., Aronson, D. C., Everts, V., and Dooren, L. J. (1993). Eur. J. Pediatr. 152, 818–821.
Schneider, G.B., Relfson, M., and Langman, C. B. (1994). J. Bone Miner. Res. 9, 585–591.
Moutier, R., Lamendin, H., and Berenholc, S. (1973). Exp. Anim. 6, 87–101.
Marks, S. C. Jr. and Popoff, S. N. (1989). Am. J. Anat. 186, 325–334.
Ek-Rylander, B., Marks, S. C. Jr., Hammarstrom, L. E., and Andersson, G. N. (1989). Bone Miner. 5, 309–321.
Nisbet, N. W., Waldron, S. F., and Marshall, M. J. (1983). Calcif. Tissue Int. 35, 122–125.
Lian, J. B. and Marks, S. C. Jr. (1990). Endocrinology 126, 955–962.
Shalboub, V., Jackson, M. E., Lian, J.B., Stein, G. S., and Marks, S. C. Jr. (1991). J. Biol. Chem. 266, 9847–9856.
Yamamoto, N., Lindsay, D. D., Naraparaju, V.R., Ireland, R. A., and Popoff, S. N. (1994). J. Immunol. 152, 5100–5107.
Brommage, R. and DeLuca, H. F. (1985). Endocr. Rev. 6, 491–511.
Henry, H. L. and Norman, A. W. (1984). Annu. Rev. Nutr. 4, 493–520.
Suda, T., Takahashi, N., and Abe, E. (1992). J. Cell Biochem. 49, 53–58.
Reynolds, J. J., Pavolvitch, H., and Balsan, S. (1976). Calcif. Tissue Int. 21, 207–212.
Wronski, T. J., Halloran, B. P., Bikle, D. D., Globus, R. K., and Morey-Holton, E. R. (1986). Endocrinology 119, 2580–2585.
Boyce, R. W., Weisbrode, S. E., and Kindig, O. (1985). Bone 6, 165–172.
Weisbrode, S. E., Capen, C. C., and Norman, A. W. (1979). Am. J. Pathol. 97, 247–254.
Klaus, G., Merke, H., Eing, U., Huggel, P., Milde, P., Reichel, H., Ritz, E., and Mehls, O. (1991). Calcif. Tissue Int. 49, 340–348.
Farquharson, C., Whitehead, C. C., Rennie, J. S., and Loveridge, N. (1993). J. Bone Miner. Res. 8, 1081–1088.
Gerstenfeld, L. C., Kelly, C. M., Von Deck, M., and Lian, J. B. (1990). Endocrinology 126, 1599–1609.
Benassi, L., Ottani, D., Fantini, F., Marconi, A., Chiodino, C., Giannetti, A., and Pincelli, C. (1997). J. Invest. Dermatol. 109, 276–282.
Pintado, C. O., Carracdo, J., Rodriguez, M., Perez-Calderon, R., and Ramirez, R. (1996). Cytokine 8, 342–345.
Marks, S. C. Jr. (1987). Appl. Pathol. 5, 172–183.
Marx, S. J. and Barsony, J. (1988). J. Bone Miner. Res. 3, 481–487.
Feldman, D. and Malloy, P. J. (1990). Mol. Cell Endocrinol. 72, C57-C62.
Sundquist, K. T., Jackson, M. E., Herméy, D. C., and Marks, S. C. Jr. (1995). Tissue Cell 27, 569–574.
Guide for the Care and Use of Laboratory Animals (1985). U.S. Dept. of Health and Human Services, National Institutes of Health Publ. No. 86-23.
Seifert, M. F. (1994). J. Bone Miner. Res. 9, 1813–1821.
Lester, D. R. and Seifert, M. F. (1996). Clin. Orthop. 330, 271–280.
Kimmel, D. B. and Jee, W. S. S. (1980). Calcif. Tissue Int. 32, 113–122.
Chambers, T. J., McSheehy, P. M. J., Thomson, B. M., and Fuller, K. (1985). Endocrinology 116, 234–239.
Reinhardt, R. A., Horst, R. L., Orf, J. W., and Hollis, B. W. (1984). J. Clin. Endocrinol. Metab. 58, 91–98.
Thiede, M. A., Smock, S. L., Petersen, D. N., Grasser, W. A., Thompson, D. D., and Nishimoto, S. K. (1994). Endocrinology 135, 929–937.
Walters, M. R., Hunziker, W., and Norman, A. W. (1981). Biochem. Biophys. Res. Commun. 98, 990–996.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Safadi, F.F., Hermey, D.C., Popoff, S.N. et al. Skeletal resistance to 1,25-dihydroxyvitamin D3 in osteopetrotic rats. Endocr 11, 309–319 (1999). https://doi.org/10.1385/ENDO:11:3:309
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:11:3:309